Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02903836 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Oral Nafithromycin in CABP
A Phase 2 study of Community-Acquired Bacterial Pneumonia (CABP), sponsored by Wockhardt.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
- 6
- Study locations
NCT02903836 is a Phase 2 study of Community-Acquired Bacterial Pneumonia (CABP) that has completed, run by Wockhardt. The registered enrollment target is 231 participants. The trial reports 6 study locations across 3 states.
The verdict
NCT02903836, a Phase 2 study of Community-Acquired Bacterial Pneumonia (CABP), has completed, sponsored by Wockhardt.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
- 6
- Study locations
Study Summary
Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
Conditions Studied
Interventions
- DRUG Nafithromycin 800 mg 3 days
- DRUG Nafithromycin 800 mg 5 days
- DRUG Moxifloxacin 400 mg
Study Locations (6)
Florida
- A & L Clinical research - Miami
- A Plus Research Inc. - Miami
- RM Medical Research, Inc. - Miami
- Empire Clinical Research, LLC - Miami Lakes
Massachusetts
- HCI Metromedic Walkin Medical Center - Bedford
South Dakota
- Health Concepts - Bedford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2016-11-18 |
| Est. Completion | 2017-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02903836
The ClinicalTrials.gov registry entry for NCT02903836 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wockhardt, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Community-Acquired Bacterial Pneumonia (CABP) appearing as the primary indexed condition, and to 3 interventions - of which Nafithromycin 800 mg 3 days is the first listed.
NCT02903836 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Florida, Massachusetts, South Dakota.
Frequently Asked Questions
What is clinical trial NCT02903836 about?
NCT02903836 is a clinical study titled "Phase II Study of Oral Nafithromycin in CABP". Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults
What is the current status of trial NCT02903836?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2016-11-18. Estimated completion is 2017-07-08.
What conditions does trial NCT02903836 study?
This clinical trial studies the following conditions: Community-Acquired Bacterial Pneumonia (CABP).
What interventions are being tested in trial NCT02903836?
The interventions under investigation include: Nafithromycin 800 mg 3 days (DRUG), Nafithromycin 800 mg 5 days (DRUG), Moxifloxacin 400 mg (DRUG).
Who is sponsoring clinical trial NCT02903836?
This trial is sponsored by Wockhardt, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02903836 being conducted?
This trial has 6 study locations across Florida, Massachusetts, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.